A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Trial Profile

A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 16 Mar 2018 Results presented in a Cellular Biomedicine Group media release.
    • 16 Mar 2018 According to a Cellular Biomedicine Group media release, 48-week clinical data was presented on March 16, 2018 at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) conference.
    • 14 Mar 2018 According to a Cellular Biomedicine Group media release, 48-week clinical data from this study will be presented at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top